A phase 3 open-label, single-arm, single-dose trial enrolled symptomatic subjects < 6-months-old (N = 22) with SMA due to biallelic SMN1 mutations (deletion or point mutations) and one or two copies of SMN2 [34]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.